Partnering
Autifony will seek strategic partners for disease areas where significant resources are required for the later stages of development and commercialisation.
Autifony is interested in discussing specific in-licensing opportunities at the preclinical or early clinical stages in hearing disorders or in CNS that address significant unmet medical needs, on a case by case basis.
Related News
07May
Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting
0 CommentsStevenage 16th April – This weekend Dr Charles Large will present key biomarker efficacy data from a first study of... Read More →
04Mar
Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders
0 CommentsStevenage, UK – 04 March 2021 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
26Aug
Autifony Therapeutics regains rights to clinical stage Kv3 programme
0 CommentsStevenage, UK – 26 August 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
04May
Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders
0 CommentsStevenage, UK – 04 May 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
30May
Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders
0 CommentsStevenage, UK – 30 May 2019 – Autifony Therapeutics Limited (“Autifony”), a clinical stage company developing new drugs to treat... Read More →
Tweets
RT @Instinctif_HLS:Great to see this exciting new collaboration between @AutifonyLtd and @Boehringer announced! https://t.co/Cx8LI319if
Autifony Therapeutics and Boehringer Ingelheim to collaborate on novel ion channel target with potential in multipl… https://t.co/KMvOWVf9o5
Autifony Therapeutics regains rights to clinical stage Kv3 programme
https://t.co/rBHjjR7aC0
Comments are closed.